No Data
No Data
Zhejiang Starry Pharmaceutical Co.,Ltd.'s (SHSE:603520) 10.0% Gain Last Week Benefited Both Retail Investors Who Own 48% as Well as Insiders
Key Insights Zhejiang Starry PharmaceuticalLtd's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 15 shareholders
Stari (603520): The inflection point in performance is now in the short term, look at costs in the medium to long term, and look at API+ formulation dosage
Matters: The company announced its 2023 annual report, achieving revenue of 2.196 billion yuan (+3.04%), net profit of 44 million yuan (+158.32%), and net profit of 36 million yuan (+136.47%) after deducting net income to mother
Stelli (603520): Marginal improvement in upstream raw material prices
The marginal decline in iodine prices for upstream raw materials in '23 drove profit side to reverse losses. It is expected to continue to improve the company's 4/29 release performance in '24, achieve revenue of 2.196 billion yuan (+3.0% yoy) in '23, and net profit of zero to mother.
Stari (603520.SH): Net profit of 12.282,500 yuan in the first quarter increased 28.37% year-on-year
On April 29, Ge Longhui (603520.SH) released its report for the first quarter of 2024, achieving operating income of 642 million yuan, an increase of 13.50%; net profit attributable to shareholders of listed companies of 12.282,500 yuan, an increase of 28.37% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 9.831 million yuan, an increase of 31.85% year on year; basic earnings per share were 0.04 yuan.
Improved Revenues Required Before Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Stock's 28% Jump Looks Justified
Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month, although it is still struggling to make up recent
These 4 Measures Indicate That Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Is Using Debt In A Risky Way
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
No Data